10-Q: Astrana Health Reports Strong Q1 2026 Growth

Astrana Health, Inc. (ASTH) announced a significant increase in revenue and net income for the first quarter of 2026, driven by strategic acquisitions and organic growth.

Summary

• Astrana Health reported total revenue of $965.1 million for the three months ended March 31, 2026, a 56% increase from $620.4 million in the same period of 2025.
• Net income attributable to Astrana Health, Inc. more than doubled to $14.4 million ($0.29 per diluted share) in Q1 2026, compared to $6.7 million ($0.14 per diluted share) in Q1 2025.
• Adjusted EBITDA increased by 82% to $66.3 million in Q1 2026 from $36.4 million in Q1 2025.
• The Prospect acquisition, completed in July 2025, contributed significantly to the revenue growth, adding $300.2 million.
• The company managed approximately 1.55 million patients as of March 31, 2026, an increase from 1.0 million patients in the prior year.
• Operating income from the Care Enablement segment saw a substantial increase of 470% to $20.2 million.
• The company has $138.0 million remaining available under its revolving credit facility as of March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, significant profit increases, and successful integration of a major acquisition, despite some noted increases in expenses and a persistent material weakness in internal controls.

Positives

• Revenue increased by 56% to $965.1 million in Q1 2026.
• Net income attributable to Astrana Health, Inc. increased by 116% to $14.4 million.
• Diluted EPS rose to $0.29 from $0.14 in the prior year's quarter.
• Adjusted EBITDA grew by 82% to $66.3 million.
• The Prospect acquisition contributed $300.2 million in revenue and $40.8 million in revenue and $13.6 million in operating income to the Care Enablement segment.
• Patient management increased to 1.55 million from 1.0 million.
• Care Enablement segment operating income surged by 470% to $20.2 million.
• Free cash flow increased significantly to $64.1 million from $13.6 million.

Negatives

• Operating income for the Care Partners segment decreased by 11% to $39.5 million, attributed to higher cost of services relative to revenue.
• Interest expense increased by 120% to $16.1 million due to increased borrowings for the Prospect acquisition.
• Depreciation and amortization expenses increased by 126% to $15.5 million, largely due to the Prospect acquisition's intangible assets.
• Net loss attributable to non-controlling interests increased to $1.3 million from $0.5 million.

Risks

• The company acknowledges a material weakness in internal control over financial reporting related to accounting for business combinations, which has not yet been remediated.
• The company is subject to complex healthcare laws and regulations, with potential for fines, penalties, or exclusion from programs if non-compliance occurs.
• The company's risk-bearing organizations must comply with DMHC regulations, including minimum working capital, tangible net equity, cash-to-claims ratio, and claims payment requirements.
• Interpretations of complex payer and provider contracts could lead to disputes over amounts due for medical services.
• The company believes its insurance coverage is appropriate but cannot guarantee it will be adequate for all future claims.
• Contracted physicians are required to obtain their own insurance, and the company's malpractice liability insurance may not be available in the future at acceptable costs or terms.

Future Outlook

The company believes it is well-positioned for the 2027 Medicare Advantage marketplace due to anticipated higher rates and stability in the risk adjustment model. Management believes the company has sufficient liquidity to fund operations through at least the next 12 months and the foreseeable future.

Management Comments

• The company believes the higher Medicare Advantage rates and commitment to risk adjustment stability in 2027 will benefit Astrana.
• Management believes Astrana is well-positioned in the 2027 Medicare Advantage marketplace.
• Management believes the company has sufficient liquidity to fund its operations through at least the next 12 months and the foreseeable future.

Industry Context

StockSavvy.ai notes that Astrana Health's strong Q1 2026 performance, particularly its revenue growth and expansion in value-based care arrangements, aligns with broader industry trends towards integrated healthcare delivery and risk-bearing models. The company's ability to leverage technology and physician networks to manage costs and improve outcomes is a key differentiator in a competitive landscape.

Comparison to Industry Standards

• Astrana Health's revenue growth of 56% in Q1 2026 significantly outpaces the typical growth rates seen in the broader healthcare services sector, which often experiences single-digit to low double-digit growth.
• The company's Adjusted EBITDA margin of 7% for Q1 2026 is competitive within the managed care and healthcare management industry, though specific benchmarks vary widely by sub-sector (e.g., MCOs vs. provider networks).
• The increase in patient lives managed to 1.55 million demonstrates significant scale, positioning Astrana Health among larger players in the value-based care space, comparable to some regional or specialized national health plans.
• The company's strategic acquisition of Prospect Medical Holdings, Inc. is a common strategy in the healthcare industry to achieve scale and expand service offerings, similar to moves made by competitors seeking to consolidate market share and enhance capabilities.

Legal Proceedings

• The company is involved in various legal proceedings arising in the normal course of business. Management believes the ultimate liability will not have a material adverse effect on financial position, results of operations, or cash flows, except for potentially material outcomes from a combination of matters.
• A previously disclosed arbitration proceeding involving CFC Health Plan, Inc. (CFC HP) was resolved by settlement and dismissed in February 2026, with the company paying a final settlement of $1.0 million in January 2026. The company sought reimbursement from escrow funds related to this matter, with no loss recovery recorded as of March 31, 2026.

Related Party Transactions

• The company incurred rent expenses from properties managed by Allied Pacific Holdings Investment Management, LLC, whose CEO is a director of Astrana.
• The company recognized risk pool revenues and had outstanding risk pool receivables with AHMC Healthcare Inc., where one of Astrana's directors is an officer.
• The company paid significant amounts to its equity method investees for services, including to Third Way Health, where an Astrana officer is also a board member.
• The company paid aggregate amounts to board members for provider services, including to Astrana board members who are also board members and officers of APC.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance and growth, but also risks associated with unaddressed internal control weaknesses and increased debt.
• Employees: Continued growth may lead to new opportunities, but increased administrative expenses and potential integration challenges could impact operations.
• Customers (Patients): Benefit from expanded network and integrated care models, aiming for higher quality and cost-effective services.
• Suppliers/Providers: Continued business relationships with potential for increased volume, but also subject to contract terms and payment cycles.
• Creditors: Increased debt levels due to acquisition financing, but company maintains sufficient liquidity and has a revolving credit facility available.

Next Steps

• Continue to evaluate and remediate the material weakness in internal control over financial reporting.
• Monitor and adapt to the final 2027 Medicare Advantage and Part D payment rates.
• Integrate acquired businesses and leverage technology to drive operational efficiency and patient care.
• Manage financial leverage and debt obligations.

Key Dates

Recommendation

Astrana Health demonstrates strong top-line growth and improved profitability, largely driven by a significant acquisition. However, the substantial increase in debt, rising interest expenses, and the persistent material weakness in internal controls warrant a cautious approach. While the outlook appears positive, investors should monitor the remediation of control issues and the integration of acquired assets before considering a more aggressive stance.

Keywords

Astrana Health, 10-Q, Healthcare Management, Value-Based Care, Medicare Advantage, Medicaid, Prospect Acquisition, Financial Results, Q1 2026, Capitation Revenue, Adjusted EBITDA